| abstract |
The invention relates to new compounds of formula (I), wherein a pharmaceutically acceptable salt, ester or amide thereof, wherein A represents O, S, CHR2, CR2 or C when n is 0, and A and R6 together form a 5-, 6- or 7-membered ring containing nitrogen, and n is 0 or 1. The dotted lines represent optional double bonds. R1 is chosen between hydrogen and an easily cleavable group. R2 is selected from hydrogen, alkyl, substituted alkyl, alkenyl and alkynyl. R3 is selected from alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, carbocyclic aryl, carbocyclic arylalkyl and a heterocycle. R4 is chosen between hydrogen and alkyl or, taken with R3 and the carbon atom to which they are attached, it forms a spirocycloalkyl ring containing 3 to 7 carbon atoms. R5 is chosen from hydrogen, alkyl and substituted alkyl or, taken with R3 and the carbon atoms to which they are attached, it forms a cycloalkyl ring comprising 5 to 7 carbon atoms. R6 is chosen from hydrogen, alkyl, acenyl, alkynyl, cycloalkyl, arylalkylcarbocyclic, alkanoyl containing 1 to 8 carbon atoms, an amino acid and bipeptide or, taken together with A when A represents C and when n is 0, it forms a 5-, 6- or 7-element ring containing nitrogen. R7 represents hydrogen or alkyl or, taken with R7 or R8, it forms a 5-, 6- or 7-membered ring containing nitrogen, provided that when R6 represents arylalkyl carbocyclic, R7 does not represent alkyl. R8 represents hydrogen or alkyl or, taken with R6 or R7, it forms a ring with 5, 6 or 7 elements containing nitrogen, or taken with the ring of pyrocatechin in position 8 and the carbon atoms to which they are fixed, it forms a ring with 5, 6 or 7 elements. The compounds of the invention are useful for treating neurological, psychological and cardiovascular disorders linked to dopamine, as well as in the treatment of cognitive impairment, disorders |